TARRYTOWN, N.Y. , Aug. 14, 2019 /PRNewswire/ -- Adding evinacumab reduced LDL cholesterol by 49% in patients with homozygous familial hypercholesterolemia, compared to lipid-lowering therapies alone Evinacumab was generally well-tolerated, and all...
Siddhartha Jaiswal is an assistant professor at Stanford University School of Medicine, where he is also a member of the Immunology Program and the Institute for Stem Cell Biology and Regenerative Medicine.
Background: Polygenic risk scores (PRS) have shown promise in predicting susceptibility to common diseases. However, the extent to which PRS and clinical risk factors act jointly and identify high-risk individuals for early onset of disease is...
Show Best Known Method, Ep 08 - Sek Kathiresan: The Inherited Mission - Aug 2, 2019
Sek Kathiresan MDHey @ethanjweiss
Such a pleasure to chat with you about genes, risk, and resistance to heart attack
the new effort @VerveTx to develop a genome-editing Rx to ultimately eradicate this disease.
Gene editing using CRISPR-Cas9 offers the potential of targeted treatment for a variety of genetic diseases. These include inherited abnormalities of β hemoglobin, which can be indirectly targeted by increasing the amount of healthy fetal hemoglobin...
Amarin stock got a boost Wednesday morning as the company posted a nice spike in Vascepa sales for the latest quarter and company execs declared themselves satisfied now that an AdCom on Vascepa is “unlikely” ahead of a late September PDUFA date....
Sek Kathiresan MDAmarin boosted as another milestone to the FDA’s big Vascepa decision flies by with no sign of an AdCom
Despite reducing progression and promoting regression of coronary atherosclerosis, statin therapy does not fully address residual cardiovascular (CV) risk. High‐purity eicosapentaenoic acid (EPA) added to a statin has been shown to reduce CV events...
Since starting as CEO of Novartis, I’ve visited about 35 countries and interacted with tens of thousands of associates across cultures and continents. The pace is relentless, and it is as demanding as it is exciting.
One of Novartis’ top Phase III catalysts this year has flunked its carefully calibrated late-stage test — but the pharma giant isn’t ready to abandon the program yet. Investigators say their PARAGON-HF study of Entresto failed in heart failure with...
Sek Kathiresan MDNovartis’ star blockbuster flunks closely watched PhIII — but they may file for key add-on OK anyway